Loading the section…

HRTX: financial statements from SEC — TradeAlmanac

HRTX

Heron Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	35M	38M	37M	39M	33M	36M
Cost of revenue	11M	12M	10M	8M	9M	11M
Gross profit	24M	26M	27M	30M	23M	26M
Research and development	2M	3M	3M	2M	4M	4M
Selling, general and administrative	12M	14M	14M	13M	12M	14M
Operating expenses	29M	30M	29M	27M	28M	32M
Operating income	−5M	−4M	−2M	3M	−4M	−6M
Net income	−8M	−17M	−2M	3M	−5M	−9M
Earnings per share	−0.04	−0.10	−0.02	0.02	−0.03	−0.06
Earnings per share, diluted	−0.04	−0.10	−0.02	0.01	−0.03	−0.06
Weighted average shares	190M	170M	154M	153M	153M	152M
Weighted average shares, diluted	190M	170M	154M	197M	153M	152M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	26M	29M	43M	17M	19M	26M	26M	18M
Receivables	84M	90M	81M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−2M	−9M
Depreciation and amortisation	529,000	551,000
Share-based compensation	3M	3M
Capital expenditure	391,000	109,000
Investing cash flow	−939,000	2M
Financing cash flow	−51,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator